Development of HCS Pharma in Taïwan with an incubation process in the famous NHRI

We are really pleased to announce that we have officially created a representative office in Taïwan (company 仿生培養技術中心 ID number 90729614) which is directed by our partner, Joseph Chou 周肇隆 ジョーゼフ・チョウ, member of our advisory board.

Thanks to Joseph and Professor Szecheng J. Lo, member of our scientific advisory board, all four major government endorsed biotech research and development institutions in Taiwan (Academia Sinica, Industrial Technology Research Institute (ITRI), Development Center for Biotechnology (DCB) and National Health Research Institutes (NHRI)) partnered with HCS Pharma to begin BIOMIMESYS® trial implementations in their laboratories.

For example, we are working in partnership with DCB to help researchers to differentiate induced pluripotent stem cells into neuronal cells in 3D by using BIOMIMESYS®. We are also working with researchers in oncology field by using BIOMIMESYS® oncology and in liver disease such as hepatitis infection by using BIOMIMESYS® liver.

In order to enhance partnerships in Taïwan, we have been accepted to be an incubate company in the technology transfer and incubation center of the National Health Research Institute (NHRI). In partnership with researchers in Europe and in Taïwan, we will combine the state of the art technologies: BIOMIMESYS® for in vitro organ-specific ECM, semiconductors for real-time analysis and microfluidic devices for dynamic implementation to develop the first 3D organ-specific biochip systems allowing to analyze cells in real time. In addition to continue the development of BIOMIMESYS® in drug discovery, we will also work in close partnership with researchers from NHRI on the use of BIOMIMESYS®in cell therapy. In the near future, we will be able to implement a new technical center in Taïwan.

We really want to thank you our partners in Taïwan, Joseph Chou and Prof Szecheng J. Lo, for their invaluable support

Image by Kim Nguyen from Pixabay.